重组人内皮抑素联合化疗改善晚期非小细胞肺癌生活质量临床的研究.docVIP

重组人内皮抑素联合化疗改善晚期非小细胞肺癌生活质量临床的研究 　　[摘要] 目的：观察抗肿瘤新药重组人血管内皮抑素注射液（恩度）联合化疗治疗晚期非小细胞肺癌（NSCLC）的疗效及其对生活质量的影响，并与单纯含铂方案比较。方法：经组织学或细胞学确诊的62例晚期非小细胞肺癌患者分为治疗组（32例）和对照组（30例），治疗组接受重组人血管内皮抑素加化疗药物联合治疗，对照组则单纯给予化疗药物治疗。按照实体瘤治疗疗效评价标准（RECIST）评价近期客观疗效，按照世界卫生组织（WHO）标准评价药物毒性。治疗1个周期后评价毒性，2个周期后评价疗效。生活质量分析采用欧洲癌症研究和治疗组织（European Organization for Research and Treatment of Cancer，EORTC）简体中文版EORTCQLQ-C30和QLQ-LC13问卷对生活质量的改变进行评估。结果：所有62 例患者均可评价疗效，其中治疗组和对照组有效率分别为25.00%、20.00%，差异无统计学意义（P＞0.05）。疾病控制率为87.50%、66.67%，差异有统计学意义（P0.05）。62例患者完成了问卷调查。治疗组患者综合生活质量的改善率高于对照组，差异有统计学意义（P0.05）。治疗组患者乏力症状的改善率高于对照组，差异有统计学意义（P0.05）。治疗组患者肺癌相关症状（咳嗽、胸痛，呼吸困难）的改善率显著高于疾病进展者（P0.05）。两组不良反应主要为疲乏、恶心呕吐、骨髓抑制。两者不良反应差异无统计学意义。结论：重组人内皮抑素联合化疗一线治疗晚期NSCLC耐受性好，可以提高化疗的疾病控制率，可改善症状提高生活质量。 　　[关键词] 重组人血管内皮抑素；非小细胞肺癌；化疗 　　[中图分类号] R734.2 [文献标识码] A [文章编号] 1673-7210（2011）11（b）-026-03 　　 　　Life quality study of rh-endostatin in combination with chemotherapy in patients with advanced non-small cell lung cancer 　　QU Yimei, LIAO Guoqing, WANG Hongmei, LIU Penghui, LI Liangliang 　　Department of Oncology, the 309th Hospital of PLA, Beijing 100091, China 　　[Abstract] Objective: To evaluate the treatment efficacy and safety of the combination of rh-endostatin (YH216) and chemot herapy in patients with advanced non-small cell lung cancer (NSCLC) and to compare with platinum-based chemotherapy alone. Methods: 62 patients with advanced non-small cell lung cancer which confirmed by histopathology or cytopathology were divided into two groups, chemotherapy group (30 cases) and endostar combined with chemotherapy group (32 cases). The efficacy of every two circle was evaluated by RESIST standard, and toxicity of every circle was evaluated by WHO standard. Before and after treatment the quality of life for non-small cell lung patients were evaluated with the Chinese versions of European Organization for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ-C30 and QLQ-LC13). Results: All cases could be evaluated of the efficacy and toxici